4Ying C,De Clercq E,Neyts J.Ribavirin and mycophenolic acid potentiate the activity of guanine-and diaminopurine-based nucleoside analogues against hepatitis B virus.Antiviral Res,2000,48(2):117 ～ 124.
5Fabrizi F,Martin P,Bunnapradist S,et al.Lamivudine in the treatment of HBV-related liver disease afte renal transplantation:an update.Int J Artif Organs,2005,28(3):211 ～ 221.
6Deeren DH,De Backer AI,Malbrain ML,et al.Treatment of hepatitis B virus-related polyarteritis nodosa:two case repoats and a review of the literature.Clin Rheumatol,2004,23:172 ～ 176.
7Akuta N,Kumada H.Influence of hepatitis B virus genotypes on the response to sntiviral therapies.J Antimicrob hemother,2005,55(2):139～ 142.
8Arosemena LR,Cortes RA,Servin L,Schiff ER.Current and future treatment of chronic hepatitis B.Minerva Gastroenterol Dietol,2005,51 (1):77 ～ 93.
9Vassiliadis T,Garipidou V,Tziomalos K,et al.Prevention of hepatitis B reactivation with lamivudine in hepatitis B virus carriers with hematologic malignancies treated with chemotherapy-a prospective case series.Am J Hematol,2005,80:197 ～ 203.
2Izeradjene K, Revillard JP. Apoptosis of superantigen-activated T cells induced by mycophenolate mofetil treatment. Transplantation,2001, 71: 118-125.
3Weimer R, Mytilineos J, Feustel A, et al. Mycophenolate mofetilbased immunosuppression and cytokine genotypes: effects on monokine secretion and antigen presentation in long-term renal transplant recipients. Transplantation, 2003, 75: 2090-2099.
4Zhou S, Liu R, Baroudy BM, et al. The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology,2003, 310: 333-342.
5Gong ZJ, De Meyer S, Clarysse C, et al. Mycophenolic acid, an immunosuppressive agent, inhibits HBV replication in vitro. J Viral Hepat, 1999, 6: 229-236.
6Streetz K, Leifeld L, Grundmann D, et al. Tumor necrosis factor alpha in the pathogenesis of human and murine fulminant hepatic failure. Gastroenterology, 2000, 119: 446-460.
7Sun Y, Tokushige K, Isono E, et al. Elevated serum interleukin-6levels in patients with acute hepatitis. J Clin Immunol, 1992, 12:197-200.
8Streetz KL, Tacke F, Leifeld L, et al. Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases.Hepatology, 2003, 38: 218-229.
